[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 37 of about 37
1. Li Z, Proud D, Zhang C, Wiehler S, McDougall JJ: Chronic arthritis down-regulates peripheral mu-opioid receptor expression with concomitant loss of endomorphin 1 antinociception. Arthritis Rheum; 2005 Oct;52(10):3210-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic arthritis down-regulates peripheral mu-opioid receptor expression with concomitant loss of endomorphin 1 antinociception.
  • OBJECTIVE: To determine whether peripheral administration of the endogenous mu-opioid peptide endomorphin 1 could reduce knee joint pain, using animal models of acute and chronic arthritis.
  • Expression of mu-opioid receptors in the dorsal root ganglia ipsilateral to the chronically inflamed joints was determined by real-time polymerase chain reaction (PCR) and immunohistochemical analysis.
  • RESULTS: In normal knees, endomorphin 1 caused up to a 75% reduction in joint afferent nerve activity, which was blocked by the mu-opioid receptor antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-amide.
  • Immunohistochemical and real-time PCR analysis of the L3-L5 dorsal root ganglia ipsilateral to the chronic arthritis lesion revealed a reduction in mu-opioid receptor protein and gene expression compared with that in normal control animals.
  • CONCLUSION: Taken together, these results provide the first electrophysiologic evidence that selective activation of peripheral mu-opioid receptors reduces normal knee joint mechanosensitivity to a noxious stimulus.
  • Furthermore, the analgesic effect of endomorphin 1 is lost during chronic inflammation due to down-regulation of mu-opioid receptor expression in afferent nerve cell bodies.
  • These findings begin to explain the ambiguous efficacy of peripherally administered mu-opioid drugs in controlling chronic inflammatory joint pain.
  • [MeSH-major] Analgesics, Opioid / pharmacology. Arthritis, Experimental / metabolism. Oligopeptides / pharmacology. Pain / drug therapy. Pain / metabolism. Receptors, Opioid, mu / metabolism
  • [MeSH-minor] Animals. Chronic Disease. Down-Regulation. Edema / metabolism. Ganglia, Spinal / cytology. Joints / innervation. Joints / metabolism. Neurons, Afferent / drug effects. Neurons, Afferent / physiology. Nociceptors / drug effects. RNA, Messenger / analysis. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Pain.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arthritis Rheum. 2005 Oct;52(10):2955-9 [16200574.001]
  • (PMID = 16200625.001).
  • [ISSN] 0004-3591
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Oligopeptides; 0 / RNA, Messenger; 0 / Receptors, Opioid, mu; 0 / endomorphin 1
  •  go-up   go-down


2. Page KA, Williamson A, Yu N, McNay EC, Dzuira J, McCrimmon RJ, Sherwin RS: Medium-chain fatty acids improve cognitive function in intensively treated type 1 diabetic patients and support in vitro synaptic transmission during acute hypoglycemia. Diabetes; 2009 May;58(5):1237-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medium-chain fatty acids improve cognitive function in intensively treated type 1 diabetic patients and support in vitro synaptic transmission during acute hypoglycemia.
  • OBJECTIVE: We examined whether ingestion of medium-chain triglycerides could improve cognition during hypoglycemia in subjects with intensively treated type 1 diabetes and assessed potential underlying mechanisms by testing the effect of beta-hydroxybutyrate and octanoate on rat hippocampal synaptic transmission during exposure to low glucose.
  • RESEARCH DESIGN AND METHODS: A total of 11 intensively treated type 1 diabetic subjects participated in stepped hyperinsulinemic- (2 mU x kg(-1) x min(-1)) euglycemic- (glucose approximately 5.5 mmol/l) hypoglycemic (glucose approximately 2.8 mmol/l) clamp studies.
  • During two separate sessions, they randomly received either medium-chain triglycerides or placebo drinks and performed a battery of cognitive tests.
  • Ingestion of medium-chain triglycerides reversed these effects.
  • Medium-chain triglycerides also produced higher free fatty acids and beta-hydroxybutyrate levels compared with placebo.
  • CONCLUSIONS: Medium-chain triglyceride ingestion improves cognition without adversely affecting adrenergic or symptomatic responses to hypoglycemia in intensively treated type 1 diabetic subjects.
  • Medium-chain triglycerides offer the therapeutic advantage of preserving brain function under hypoglycemic conditions without causing deleterious hyperglycemia.

  • Genetic Alliance. consumer health - Hypoglycemia.
  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • MedlinePlus Health Information. consumer health - Hypoglycemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Food Chem Toxicol. 2000 Jan;38(1):79-98 [10685018.001]
  • [Cites] J Neurophysiol. 2003 Aug;90(2):613-21 [12724360.001]
  • [Cites] Diabetes. 2004 Feb;53(2):418-25 [14747293.001]
  • [Cites] Am J Clin Nutr. 2004 Apr;79(4):564-9 [15051598.001]
  • [Cites] Arch Dis Child. 1970 Aug;45(242):445-52 [4918706.001]
  • [Cites] Biochem J. 1971 Mar;122(1):13-8 [5124783.001]
  • [Cites] Science. 1979 Jul 20;205(4403):325-7 [451608.001]
  • [Cites] Am J Clin Nutr. 1983 Jan;37(1):1-4 [6849272.001]
  • [Cites] Acta Neuropathol. 1984;64(3):177-91 [6496035.001]
  • [Cites] J Neurosci Res. 1987;18(4):551-61 [3481403.001]
  • [Cites] Metabolism. 1989 Jul;38(7):641-8 [2739575.001]
  • [Cites] J Neurochem. 1991 Apr;56(4):1376-86 [2002348.001]
  • [Cites] Clin Sci (Lond). 1991 Aug;81(2):189-94 [1653662.001]
  • [Cites] Neurosci Lett. 1991 Sep 2;130(1):53-6 [1749516.001]
  • [Cites] Diabetes. 1992 May;41(5):641-7 [1568535.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):977-86 [8366922.001]
  • [Cites] J Cereb Blood Flow Metab. 1994 Jan;14(1):125-31 [8263048.001]
  • [Cites] Lancet. 1994 Jan 1;343(8888):16-20 [7905041.001]
  • [Cites] Diabetes. 1994 Nov;43(11):1311-7 [7926305.001]
  • [Cites] Experientia. 1995 Mar 15;51(3):213-6 [7698281.001]
  • [Cites] Ann Nucl Med. 1995 Aug;9(3):137-42 [8534586.001]
  • [Cites] J Cereb Blood Flow Metab. 2000 Oct;20(10):1502-7 [11043913.001]
  • [Cites] Am J Clin Nutr. 1997 Jan;65(1):41-5 [8988911.001]
  • [Cites] Diabetes. 1997 Feb;46(2):271-86 [9000705.001]
  • [Cites] Stroke. 1997 Mar;28(3):584-7 [9056615.001]
  • [Cites] J Am Diet Assoc. 1997 Jun;97(6):605-11 [9183320.001]
  • [Cites] J Clin Invest. 1998 Mar 1;101(5):1121-32 [9486983.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Aug;83(8):2952-9 [9709975.001]
  • [Cites] J Cereb Blood Flow Metab. 2006 Jan;26(1):142-52 [15973352.001]
  • [Cites] Diabet Med. 2006 Jan;23(1):26-31 [16409562.001]
  • [Cites] Diabetes. 2006 Apr;55(4):929-34 [16567513.001]
  • [Cites] Diabetes. 2006 Apr;55(4):1121-6 [16567537.001]
  • [Cites] Metabolism. 2007 Jul;56(7):985-91 [17570262.001]
  • [Cites] Diabetes. 2008 Jul;57(7):1905-17 [18390791.001]
  • [Cites] Neurochem Int. 2008 Jul;53(1-2):22-32 [18534717.001]
  • [Cites] J Physiol Biochem. 2000 Dec;56(4):337-46 [11321528.001]
  • [Cites] J Nutr. 2002 Mar;132(3):329-32 [11880549.001]
  • [Cites] Neuroscience. 2002;113(1):11-21 [12123680.001]
  • [Cites] J Cereb Blood Flow Metab. 2002 Jul;22(7):890-8 [12142574.001]
  • [Cites] Biosci Biotechnol Biochem. 2002 Aug;66(8):1713-8 [12353632.001]
  • [Cites] Int J Obes Relat Metab Disord. 2003 Jan;27(1):95-102 [12532160.001]
  • [Cites] Diabetes Care. 2003 Feb;26(2):390-6 [12547868.001]
  • [Cites] Biosci Biotechnol Biochem. 2003 Jan;67(1):46-53 [12619672.001]
  • [Cites] J Neurosci. 2003 Jul 2;23(13):5928-35 [12843297.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2881-5 [10706633.001]
  • (PMID = 19223595.001).
  • [ISSN] 1939-327X
  • [Journal-full-title] Diabetes
  • [ISO-abbreviation] Diabetes
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R37 DK20495; United States / NIDDK NIH HHS / DK / R01 DK069831; United States / NCRR NIH HHS / RR / UL1 RR024139; United States / NINDS NIH HHS / NS / NS045792-03; United States / NINDS NIH HHS / NS / R01 NS045792-03; United States / NINDS NIH HHS / NS / R01 NS045792; United States / PHS HHS / / R01NA045792; United States / NIDDK NIH HHS / DK / DK069831; United States / NIDDK NIH HHS / DK / R37 DK020495
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fatty Acids, Nonesterified; 0 / Triglycerides; TZP1275679 / 3-Hydroxybutyric Acid
  • [Other-IDs] NLM/ PMC2671041
  •  go-up   go-down


3. Audard V, Georges B, Vanhille P, Toly C, Deroure B, Fakhouri F, Cuvelier R, Belenfant X, Surin B, Aucouturier P, Mougenot B, Ronco P: Renal lesions associated with IgM-secreting monoclonal proliferations: revisiting the disease spectrum. Clin J Am Soc Nephrol; 2008 Sep;3(5):1339-49
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal lesions associated with IgM-secreting monoclonal proliferations: revisiting the disease spectrum.
  • BACKGROUND AND OBJECTIVES: Since the first description of pathology of the kidney in Waldenström disease in 1970, there have been few reports on kidney complications of IgM-secreting monoclonal proliferations.
  • Here, we aimed to revisit the spectrum of renal lesions occurring in patients with a serum monoclonal IgM.
  • DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Fourteen patients with a circulating monoclonal IgM and a kidney disease related to B cell proliferation were identified retrospectively.
  • Demographic, clinical, and laboratory data were assessed for each patient at the time of kidney biopsy.
  • For five patients, the diagnosis of monoclonal IgM preceded the kidney disease by 28.8 mo (range 12 to 60).
  • Seven patients had Waldenström disease, two had a small B cell non-Hodgkin lymphoma, one had an IgM-excreting multiple myeloma, one had a marginal zone B cell lymphoma, and three had an IgM-related disorder.
  • Renal lesions included (1) intracapillary monoclonal deposits disease with granular, electron-dense IgM thrombi occluding capillary lumens (5);.
  • (3) lambda light chain amyloidosis (2) associated with mu deposits in one patient;.
  • Remission of the nephrotic syndrome was attained in three of seven patients, and renal function improved after chemotherapy.
  • CONCLUSIONS: Although renal complications of IgM proliferations are rare, a wide spectrum of kidney lesions is observed, without correlation with the type of hematologic disorder.
  • [MeSH-major] Antibodies, Monoclonal / analysis. B-Lymphocytes / immunology. Cell Proliferation. Immunoglobulin M / analysis. Kidney Diseases / immunology. Lymphoproliferative Disorders / immunology
  • [MeSH-minor] Aged. Amyloidosis / immunology. Female. Glomerulonephritis, Membranoproliferative / immunology. Humans. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell, Marginal Zone / immunology. Male. Middle Aged. Multiple Myeloma / immunology. Nephrotic Syndrome / immunology. Retrospective Studies. Treatment Outcome. Waldenstrom Macroglobulinemia / immunology

  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2003 Apr;30(2):110-5 [12720118.001]
  • [Cites] Am J Nephrol. 1985;5(1):53-8 [3918448.001]
  • [Cites] Am J Kidney Dis. 2004 May;43(5):e23-8 [15112195.001]
  • [Cites] Crit Care. 2004 Aug;8(4):R204-12 [15312219.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(17):6542-6 [2118650.001]
  • [Cites] N Engl J Med. 1991 Jun 27;324(26):1845-51 [1904132.001]
  • [Cites] J Clin Oncol. 1993 May;11(5):914-20 [8487054.001]
  • [Cites] Am J Hematol. 1994 Feb;45(2):171-6 [8141123.001]
  • [Cites] Clin Sci (Lond). 1994 Nov;87(5):487-91 [7874834.001]
  • [Cites] Nephrol Dial Transplant. 1997 Jun;12(6):1256-9 [9198063.001]
  • [Cites] Clin Nephrol. 1998 May;49(5):325-7 [9617499.001]
  • [Cites] Nephrol Dial Transplant. 1998 Oct;13(10):2630-2 [9794573.001]
  • [Cites] Kidney Int. 1999 Jul;56(1):355-77 [10411717.001]
  • [Cites] Am J Kidney Dis. 2005 Apr;45(4):749-57 [15806478.001]
  • [Cites] Clin Nephrol. 2005 Nov;64(5):396-9 [16312271.001]
  • [Cites] Am J Kidney Dis. 2006 May;47(5):908-14 [16632032.001]
  • [Cites] Am J Kidney Dis. 2006 Jul;48(1):e3-9 [16797380.001]
  • [Cites] Nephrol Dial Transplant. 2007 Feb;22(2):627-30 [17164317.001]
  • [Cites] Clin J Am Soc Nephrol. 2006 Nov;1(6):1342-50 [17699367.001]
  • [Cites] J Hypertens. 2007 Sep;25(9):1751-62 [17762635.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):122-5 [10665924.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:3-10 [10707771.001]
  • [Cites] Br J Haematol. 2000 Sep;110(4):880-3 [11054074.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1058-66 [11287977.001]
  • [Cites] Am J Kidney Dis. 2001 Aug;38(2):395-9 [11479168.001]
  • [Cites] Nephron. 2002 Jul;91(3):512-5 [12119489.001]
  • [Cites] Nephron. 2002 Oct;92(2):452-5 [12218329.001]
  • [Cites] Am J Surg Pathol. 2003 Apr;27(4):541-5 [12657941.001]
  • [Cites] Medicine (Baltimore). 2008 Mar;87(2):99-109 [18344807.001]
  • [Cites] N Engl J Med. 2004 Oct 28;351(18):1860-73 [15509819.001]
  • [Cites] N Engl J Med. 1970 Jul 16;283(3):123-9 [4987279.001]
  • [Cites] Arch Intern Med. 1975 Jan;135(1):40-5 [803364.001]
  • [Cites] Nephron. 1984;38(3):156-62 [6436718.001]
  • [Cites] Lancet Oncol. 2003 Nov;4(11):679-85 [14602248.001]
  • (PMID = 18632851.001).
  • [ISSN] 1555-905X
  • [Journal-full-title] Clinical journal of the American Society of Nephrology : CJASN
  • [ISO-abbreviation] Clin J Am Soc Nephrol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunoglobulin M
  • [Other-IDs] NLM/ PMC2518806
  •  go-up   go-down


Advertisement
4. Mu W, Ouyang X, Agarwal A, Zhang L, Long DA, Cruz PE, Roncal CA, Glushakova OY, Chiodo VA, Atkinson MA, Hauswirth WW, Flotte TR, Rodriguez-Iturbe B, Johnson RJ: IL-10 suppresses chemokines, inflammation, and fibrosis in a model of chronic renal disease. J Am Soc Nephrol; 2005 Dec;16(12):3651-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IL-10 suppresses chemokines, inflammation, and fibrosis in a model of chronic renal disease.
  • Whereas short-term administration of IL-10 has shown benefit in acute glomerulonephritis, no studies have addressed the potential benefits of IL-10 in chronic renal disease.
  • Four weeks after injection, IL-10 levels in serum were measured by ELISA, and chronic renal disease was induced by a 5/6 nephrectomy (n = 6 in each group).
  • Eight weeks later, rats were killed and renal tissue was obtained for RNA, protein, and immunohistochemical analysis.
  • Serum levels of IL-10 were 12-fold greater in the rAAV1-IL-10 group by 4 wk after rAAV1-IL-10 administration (345 +/- 169 versus 28 +/- 15 pg/ml; P = 0.001), and levels were maintained throughout the experiment. rAAV1-IL-10 treatment resulted in less proteinuria (P < 0.05), lower serum creatinine (P < 0.05), and higher creatinine clearances (P < 0.01) compared with rAAV1-GFP-treated rats.
  • The reduction in inflammatory cells was associated with a significant reduction in glomerulosclerosis and interstitial fibrosis.
  • It is concluded that IL-10 blocks inflammation and improves renal function in this model of chronic renal disease.
  • The feasibility of long-term overexpression of a gene using the AAV serotype 1 vector system in a model of renal disease is also demonstrated.
  • [MeSH-major] Chemokines / metabolism. Interleukin-10 / blood. Interleukin-10 / pharmacology. Kidney Failure, Chronic / drug therapy. Kidney Failure, Chronic / pathology. Nephritis, Interstitial / pathology
  • [MeSH-minor] Animals. Biopsy, Needle. Cytokines / drug effects. Cytokines / metabolism. Disease Models, Animal. Fibrosis / drug therapy. Fibrosis / pathology. Gene Expression Regulation. Immunohistochemistry. Kidney Function Tests. Male. Proteinuria / physiopathology. RNA, Messenger / analysis. RNA, Messenger / genetics. Rats. Rats, Sprague-Dawley. Reference Values. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16251240.001).
  • [ISSN] 1046-6673
  • [Journal-full-title] Journal of the American Society of Nephrology : JASN
  • [ISO-abbreviation] J. Am. Soc. Nephrol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK-52121; United States / NIDDK NIH HHS / DK / DK-64322; United States / NHLBI NIH HHS / HL / HL-68607
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chemokines; 0 / Cytokines; 0 / RNA, Messenger; 130068-27-8 / Interleukin-10
  •  go-up   go-down


5. Vinuesa M, Bassan N, Cases AI, Krumrik G: Montelukast treatment (cysteinyl leukotriene receptor antagonist) in a model of food allergy: modifications in lymphatic cell population from rectal mucosa. Rev Esp Enferm Dig; 2010 Jul;102(7):421-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Montelukast treatment (cysteinyl leukotriene receptor antagonist) in a model of food allergy: modifications in lymphatic cell population from rectal mucosa.
  • Results were expressed as arithmetic mean and SE.
  • Anti -CD4, CD5, micro chain monoclonal antibodies were used.
  • CD 5: G1: 7.3 +/- 0.05; G2: 9.4 +/- 0.05, G3: 11.3 +/- 0.06, G4: 8.1 +/- 0.06. mu chain: G1: 10.4 +/- 0.06; G2: 3.8 +/- 0.02, G3: 6.0 +/- 0.10, G4: 2.2 +/- 0.10.
  • CD4+, CD5+ cells and mu chain+ decrease in experimental group (G4), probably due to lymphocyte migration inhibition to challenged mucosa. mu chain+ cell decrease could be based on B cell activation and expression of different surface immunoglobulins.
  • Cells expressing mu chain decreased in G2 and G3 likely due to activation of B cells and subsequent expression of other immunoglobulin chains in cell surface.
  • CONCLUSIONS: We conclude that obtained data are important to elucidate immunopathology of local anaphylactic reaction in rectal mucosa from systemic sensitized animals after treatment with montelukast.
  • [MeSH-major] Acetates / therapeutic use. Disease Models, Animal. Food Hypersensitivity / drug therapy. Intestinal Mucosa / cytology. Intestinal Mucosa / immunology. Leukotriene Antagonists / therapeutic use. Quinolines / therapeutic use

  • MedlinePlus Health Information. consumer health - Food Allergy.
  • Hazardous Substances Data Bank. MONTELUKAST .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20617862.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Acetates; 0 / Leukotriene Antagonists; 0 / Quinolines; MHM278SD3E / montelukast
  •  go-up   go-down


6. Thomas RM, Brems JJ, Guzman-Hartman G, Yong S, Cavaliere P, Van Thiel DH: Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl; 2003 Sep;9(9):905-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation.
  • An analysis of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplant Registry data shows that the greater the viral load at the time of transplantation, the more rapidly clinically evident posttransplantation hepatitis C virus (HCV) disease recurs.
  • These data suggest that aggressive pretransplantation treatment of HCV might delay recurrent posttransplantation HCV disease and enhance posttransplantation survival.
  • We have taken an aggressive approach to treating HCV infection pretransplantation with the use of high-dose (5 MU) daily interferon alpha(2b) in an effort to clear the virus before transplantation.
  • There were 22 men and five women, with a mean age of 56 +/- 2 years.
  • The majority had genotype 1 disease (67%).
  • Of the 27 patients, 7 had a baseline platelet count <50,000/mm(3) and were excluded from interferon therapy.
  • Twelve (60%) responded to the therapy with serologic clearance of HCV before OLT.
  • The mean time from initiation of therapy to the first negative qualitative polymerase chain reaction was 4.5 +/- 1.5 (range, 0.5 to 12) months.
  • One third of patients, in whom the HCV cleared before OLT, did not have evidence of disease recurrence after OLT.
  • It is thus anticipated that with early and aggressive pre-OLT HCV therapy, possibly with the use of pegylated interferon, even better results may be obtained.
  • [MeSH-major] Antiviral Agents / administration & dosage. Hepatitis C, Chronic / drug therapy. Hepatitis C, Chronic / surgery. Interferon-alpha / administration & dosage. Liver Transplantation

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12942451.001).
  • [ISSN] 1527-6465
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


7. Yao H, Pan J, Qian Y, Pei Z, Bader A, Brockmeyer NH, Altmeyer P, Zhang L: Enhanced effect of soluble transforming growth factor-beta receptor II and IFN-gamma fusion protein in reversing hepatic fibrosis. Eur J Med Res; 2010 Apr 8;15(4):152-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 2) RsTbetaRII-IFN-gamma treatment group (each rat, 0.136 mg x day(-1);.
  • 3) IFN-gamma treatment group (each rat, 7.5 MU x day(-1);.
  • 4) RsTbetaRII treatment group (each rat, 0.048 mg x day(-1); and 5) mixture of IFN-gamma and RsTbetaRII treatment group (each rat, IFN-gamma 7.5 MU x day(-1)+ RsTbetaRII 0.048 mg x day(-1).
  • After treatment, hepatic fibrogenesis was evaluated by histopathological analysis and measurement of collagen III, alpha-smooth muscle actin (alpha-SMA), TGF-beta1, TGF-betaRII and their mRNA.
  • RESULTS: Immunohistochemistry, Western blot and real-time RT-PCR showed that RsTbetaRII-IFN-gamma treatment significantly inhibited liver expression of collagen III, alpha-SMA, TGF-beta1 and TGF-betaRII at both protein and mRNA levels.
  • [MeSH-major] Interferon-gamma / therapeutic use. Liver Cirrhosis / drug therapy. Protein-Serine-Threonine Kinases / therapeutic use. Receptors, Transforming Growth Factor beta / therapeutic use. Recombinant Fusion Proteins / therapeutic use
  • [MeSH-minor] Animals. Carbon Tetrachloride / toxicity. DNA Primers. Disease Models, Animal. Gene Amplification. Liver / drug effects. Liver / pathology. Polymerase Chain Reaction. Rats. Rats, Sprague-Dawley

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • Hazardous Substances Data Bank. CARBON TETRACHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1999 Feb 25;397(6721):710-3 [10067896.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2345-9 [10051644.001]
  • [Cites] Hepatology. 1999 Jun;29(6):1730-8 [10347115.001]
  • [Cites] Zhejiang Da Xue Xue Bao Yi Xue Ban. 2005 Jan;34(1):43-7, 54 [15693123.001]
  • [Cites] Gene Ther. 2005 May;12(9):742-50 [15729371.001]
  • [Cites] Int J Mol Med. 2005 Jul;16(1):59-64 [15942678.001]
  • [Cites] Dig Dis Sci. 2006 May;51(5):986-95 [16642426.001]
  • [Cites] Hepatology. 2006 Sep;44(3):612-22 [16941698.001]
  • [Cites] J Biol Chem. 2006 Dec 29;281(52):39757-65 [17060319.001]
  • [Cites] J Hepatol. 2007 Feb;46(2):295-303 [17125875.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Jan;22(1):99-111 [17201889.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12719-24 [10535989.001]
  • [Cites] Hum Gene Ther. 2000 Jan 1;11(1):33-42 [10646637.001]
  • [Cites] J Biol Chem. 2000 Jan 28;275(4):2247-50 [10644669.001]
  • [Cites] Parasite Immunol. 2001 Jan;23(1):11-7 [11136473.001]
  • [Cites] Clin Liver Dis. 2000 May;4(2):319-55 [11232195.001]
  • [Cites] Gene Ther. 2001 Sep;8(17):1333-42 [11571570.001]
  • [Cites] Hepatology. 2002 May;35(5):1022-30 [11981752.001]
  • [Cites] J Hepatol. 2003 Nov;39(5):731-7 [14568254.001]
  • [Cites] Am J Pathol. 2004 Apr;164(4):1389-97 [15039226.001]
  • [Cites] Immunol Lett. 2004 Jun 15;94(1-2):141-51 [15234546.001]
  • [Cites] Prog Liver Dis. 1990;9:143-55 [2156289.001]
  • [Cites] J Clin Invest. 1990 Nov;86(5):1641-8 [2243137.001]
  • [Cites] J Clin Invest. 1992 Jul;90(1):1-7 [1634602.001]
  • [Cites] Nature. 1992 Nov 26;360(6402):361-4 [1280332.001]
  • [Cites] J Hepatol. 1992 Nov;16(3):282-9 [1487604.001]
  • [Cites] N Engl J Med. 1994 Nov 10;331(19):1286-92 [7935686.001]
  • [Cites] J Clin Invest. 1995 Jul;96(1):447-55 [7615817.001]
  • [Cites] J Hepatol. 1997 Apr;26(4):894-903 [9126805.001]
  • [Cites] Mol Cell Biol. 1997 Sep;17(9):5201-9 [9271398.001]
  • [Cites] J Hepatol. 1998 Aug;29(2):263-70 [9722208.001]
  • [Cites] Annu Rev Biochem. 1998;67:753-91 [9759503.001]
  • [Cites] J Hepatol. 1999 Jan;30(1):77-87 [9927153.001]
  • [Cites] Circ Res. 1999 May 28;84(10):1212-22 [10347096.001]
  • (PMID = 20554496.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Receptors, Transforming Growth Factor beta; 0 / Recombinant Fusion Proteins; 82115-62-6 / Interferon-gamma; CL2T97X0V0 / Carbon Tetrachloride; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  • [Other-IDs] NLM/ PMC3474166
  •  go-up   go-down


8. Yanai M, Maeda A, Watanabe N, Sugimoto N, Matsushita A, Nagai K, Oida T, Takahashi T: Successful treatment of mu-heavy chain disease with fludarabine monophosphate: a case report. Int J Hematol; 2004 Feb;79(2):174-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of mu-heavy chain disease with fludarabine monophosphate: a case report.
  • Heavy chain diseases (HCD) are monoclonal lymphoproliferative disorders of B-cells characterized by the synthesis of truncated heavy chains without associated light chains.
  • In patients with mu-HCD, which is a very rare form of HCD, neoplastic cells produce immunoglobulin M heavy chain.
  • The prognosis for patients with mu-HCD is poor, and there is no specific treatment for mu-HCD.
  • In this report, we present a patient with mu-HCD accompanied by splenomegaly and thrombocytopenia.
  • We treated this patient with the fludarabine monophosphate therapy we use for patients with B-cell chronic lymphocytic leukemia.
  • After 5 courses of fludarabine monophosphate treatment, the splenomegaly and thrombocytopenia improved.
  • Fludarabine monophosphate therapy may be a new strategy to improve the prognosis of patients with mu-HCD.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Heavy Chain Disease / drug therapy. Vidarabine Phosphate / administration & dosage. Vidarabine Phosphate / analogs & derivatives

  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for heavy chain disease .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1971 Sep;75(3):407-14 [5568152.001]
  • [Cites] Ann Hematol. 1998 Nov;77(5):231-4 [9858149.001]
  • [Cites] Int J Hematol. 1997 Oct;66(3):359-65 [9401282.001]
  • [Cites] Clin Chem. 1974 Oct;20(10):1292-4 [4213365.001]
  • [Cites] Am J Med. 1973 Jan;54(1):127-35 [4629971.001]
  • [Cites] Blood. 1974 Apr;43(4):485-92 [4361394.001]
  • [Cites] Int J Hematol. 2001 Jan;73(1):32-8 [11372752.001]
  • [Cites] Blood. 1974 May;43(5):713-9 [4206914.001]
  • [Cites] Scand J Haematol. 1976 Mar;16(3):209-17 [179130.001]
  • [Cites] Arch Intern Med. 1979 Jun;139(6):672-4 [109059.001]
  • [Cites] Am J Med. 1978 Aug;65(2):334-41 [99035.001]
  • [Cites] Am J Hematol. 1992 May;40(1):56-60 [1566748.001]
  • [Cites] Immunology. 1970 Jul;19(1):137-49 [4098592.001]
  • [Cites] Br J Rheumatol. 1987 Dec;26(6):460-2 [3120844.001]
  • [Cites] N Engl J Med. 1970 May 7;282(19):1060-2 [5438427.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):44-9 [1702145.001]
  • [Cites] Hematol Oncol Clin North Am. 1999 Dec;13(6):1281-94 [10626151.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):175-88 [1702143.001]
  • [Cites] Clin Nephrol. 1997 Aug;48(2):118-21 [9285150.001]
  • (PMID = 15005347.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 106XV160TZ / Vidarabine Phosphate; 1X9VK9O1SC / fludarabine phosphate
  • [Number-of-references] 22
  •  go-up   go-down


9. Witzig TE, Wahner-Roedler DL: Heavy chain disease. Curr Treat Options Oncol; 2002 Jun;3(3):247-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heavy chain disease.
  • The heavy chain diseases (HCDs) are rare B-cell malignancies that are distinguished by the production of a monoclonal immunoglobulin heavy chain (HC) without an associated light chain by the malignant B-cells.
  • There are three types of HCD defined by the class of immunoglobulin (Ig) HC produced: IgA (alpha-HCD), IgG (gamma-HCD), and IgM (mu-HCD).
  • Alpha-HCD is the most common and occurs most commonly as intestinal malabsorption in a young adult from a country bordering the Mediterranean Sea.
  • Treatment consists of antibiotics and improved nutrition and hygiene.
  • If there is no response to antibiotics or if aggressive non-Hodgkin's lymphoma (NHL) is diagnosed, the patient should be treated with chemotherapy.
  • Gamma- and mu-HCD are rare and essentially are found in patients with a B-cell NHL that produces an abnormal Ig heavy chain.
  • These patients occasionally may be diagnosed with a monoclonal gammopathy of undetermined significance (MGUS).
  • Patients with MGUS with NHL should be administered chemotherapy.
  • Screening the serum and urine of patients with lymphoplasmacytoid NHL would likely identify more patients with gamma- or mu-HCD.
  • [MeSH-major] Heavy Chain Disease / therapy
  • [MeSH-minor] Adult. Aged. Gene Rearrangement, B-Lymphocyte, Heavy Chain / genetics. Humans. Immunoglobulin Heavy Chains / genetics. Incidence. Middle Aged. Radiotherapy

  • COS Scholar Universe. author profiles.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for heavy chain disease .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Rheumatol. 2000 Jan;12(1):65-70 [10647957.001]
  • [Cites] Histopathology. 1990 Jul;17(1):7-17 [2227833.001]
  • [Cites] J Clin Gastroenterol. 1998 Jul;27(1):85-9 [9706780.001]
  • [Cites] Ann Hematol. 1998 Nov;77(5):231-4 [9858149.001]
  • [Cites] Int J Hematol. 1997 Oct;66(3):359-65 [9401282.001]
  • [Cites] Rev Prat. 1993 Feb 1;43(3):317-20 [8502962.001]
  • [Cites] Mayo Clin Proc. 1987 Aug;62(8):719-31 [3110508.001]
  • [Cites] Clin Chem. 1994 Apr;40(4):664 [8149622.001]
  • [Cites] Arch Pathol Lab Med. 1986 Oct;110(10):893-6 [3094476.001]
  • [Cites] Br J Surg. 1994 Jan;81(1):20-4 [8313111.001]
  • [Cites] Eur J Haematol. 1995 Mar;54(3):202-4 [7720844.001]
  • [Cites] J Am Acad Dermatol. 1990 Nov;23(5 Pt 2):988-91 [2121807.001]
  • [Cites] Am J Clin Oncol. 1996 Feb;19(1):18-22 [8554029.001]
  • [Cites] Am J Med. 1990 Oct;89(4):483-90 [2145762.001]
  • [Cites] Br J Haematol. 2000 Mar;108(4):737-42 [10792277.001]
  • [Cites] Br J Haematol. 1994 Nov;88(3):653-5 [7819086.001]
  • [Cites] Cancer. 1997 Jul 1;80(1):8-14 [9210703.001]
  • [Cites] Springer Semin Immunopathol. 1990;12(2-3):239-50 [2205943.001]
  • [Cites] Gastroenterol Clin Biol. 1985 Jun-Jul;9(6-7):472-9 [3926586.001]
  • [Cites] Hum Pathol. 1984 Feb;15(2):122-9 [6421714.001]
  • [Cites] Am J Hematol. 1992 May;40(1):56-60 [1566748.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2463-8 [9482908.001]
  • [Cites] Am J Clin Pathol. 1982 Oct;78(4):427-36 [6814232.001]
  • [Cites] Med Pediatr Oncol. 1995 Nov;25(5):400-6 [7674998.001]
  • [Cites] J Clin Oncol. 1994 Jul;12(7):1375-82 [8021727.001]
  • [Cites] Hematol Oncol Clin North Am. 1999 Dec;13(6):1281-94 [10626151.001]
  • [Cites] Am J Gastroenterol. 1999 May;94(5):1139-52 [10235185.001]
  • [Cites] Z Gastroenterol. 1995 Apr;33(4):209-13 [7793120.001]
  • [Cites] Clin Chem. 1981 Feb;27(2):331-3 [7460288.001]
  • [Cites] Mayo Clin Proc. 1981 Jul;56(7):439-51 [6789012.001]
  • [Cites] Recent Results Cancer Res. 1978;64:271-6 [104370.001]
  • [Cites] Cancer. 1989 Apr 1;63(7):1251-6 [2920354.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Gut. 1978 Jul;19(7):627-31 [98395.001]
  • (PMID = 12057070.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  • [Number-of-references] 36
  •  go-up   go-down


10. Adam Z, Krejcí M, Pour L, Stepánková S, Cermáková Z, Voska L, Teplan V, Krivanová A, Hájek R, Mayer J: [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature]. Vnitr Lek; 2009 Nov;55(11):1089-96
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
  • [Transliterated title] Vymizení nefrotického syndromu a zlepsení funkce ledvin u nemocné s light chain deposition disease po vysokodávkované chemoterapii s autologní transplantací kmenových krvetvorných bunek. Popis prípadu a prehled literatury.
  • Light chain deposition disease (LCDD) damages most frequently kidneys, and less frequently other organs.
  • Renal biopsy specimen revealed the diagnosis of LCDD.
  • These findings confirmed the diagnosis of multiple myeloma (MM) Durie Salmon stage IB with LCDD.
  • The patient was initially treated with 4 cycles of VAD (vinkristine, adriamycine, dexamethasone) chemotherapy with no response.
  • Followed collection of peripheral haematopoietic stem cells and later high dose chemotherapy with reduced dose of melphalan 140 mg/sqm and autologous peripheral haematopoietic stem cells transplantation.
  • High dose therapy was complicated by with deterioration of renal function, creatinine increased to 600 micromol/l.
  • Follow-up examination one month after high dose chemotherapy showed complete remission, that was confirmed by further examinations.
  • In the course of the first year after high dose chemotherapy renal function gradually improved and nephrotic syndrome completely disappeared (complete kidney remission).
  • Three years after high dose chemotherapy the patient is still in complete remission of multiple myeloma and free of nephrotic syndrome, with slightly increased creatinine (160 micromol/l) that, nevertheless, has had an improving tendency over last 3 years.
  • The present case study illustrates accomplishment of complete haematological remission with high dose chemotherapy followed by autologous haematopoietic stem cells transplantation despite complete resistance of the disease to the standard chemotherapy VAD in a patient with MM and LCDD.
  • We draw the reader's attention to the possibility of nephrotoxic effects of high dose melphalan (post conditioning renal insufficiency) in patients with nephrotic syndrome caused by light chain deposits as AL-amyloid or amorphous light chains deposits (LCDD)and we document the importance of plasma free light chain detection.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Immunoglobulin Light Chains / immunology. Multiple Myeloma / therapy. Nephrotic Syndrome / physiopathology
  • [MeSH-minor] Adult. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Combined Modality Therapy. Drug Resistance, Neoplasm. Female. Humans. Kidney / pathology. Melphalan / administration & dosage. Melphalan / adverse effects. Remission Induction. Transplantation, Autologous

  • Genetic Alliance. consumer health - Light chain deposition disease.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20017442.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Immunoglobulin Light Chains; Q41OR9510P / Melphalan
  • [Number-of-references] 48
  •  go-up   go-down


11. Adam Z, Nedbálková M, Krejcí M, Pour L, Husek K, Veselý K, Cermáková Z, Krivanová A, Mayer J, Hájek R: [More than 10 years of complete remission of monoclonal gammopathy of undetermined significance and cessation of light chain deposition disease-associated nephrotic syndrome following treatment with vincristine, adriamycin and high-dose dexamethasone (VAD)]. Vnitr Lek; 2010 Mar;56(3):240-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [More than 10 years of complete remission of monoclonal gammopathy of undetermined significance and cessation of light chain deposition disease-associated nephrotic syndrome following treatment with vincristine, adriamycin and high-dose dexamethasone (VAD)].
  • [Transliterated title] Více nez 10 let trvající kompletní remise monoklonální gamapatie nejistého významu a vymizení nefrotického syndromu vzniklého na podkladne light chain deposition disease po lécbe vinkristinem, adriamycinem a vysokými dávkami dexametazonu (VAD).
  • Light chain deposits in the form of amorphous material (light chain deposition disease) damage most frequently kidneys and, less frequently, they affect other organs.
  • The incidence of light chain deposition disease is much lower than that of AL-amyloidosis.
  • Symmetrical swelling of both legs, swelling of the eye lids, erythrocyturia and nephrotic proteinuria were the first signs of light chain deposition disease in our patient.
  • The disease was diagnosed from kidney biopsy performed at the stage of advanced nephrotic syndrome with reduced filtration.
  • However, 2 months after the completion of chemotherapy, the immunofixation electrophoresis had become negative and thus complete haematological treatment response (remission) was achieved.
  • Proteinuria declined below 1 g/l and no erythrocyturia was present 4 years post-treatment.
  • Proteinuria declined to 0.19 g/I, i.e., normal values, 9 years post-treatment completion.
  • Regular follow-ups in patients with MGUS should seek to identify not only whether MGUS is transforming into malignant disease but also whether monoclonal immunoglobulin is damaging the organism.
  • Treatment of patients with monoclonal immunoglobulin-associated damage should be initiated early as the restoration of the affected organs function (organ treatment response) after complete haematological remission is only gradual.
  • At present, treatment regimes with high-dose dexamethasone are recommended for patients with primary systemic AL-amyloidosis.
  • We believe that the same approach is suitable for the treatment of light chain deposition disease in MGUS patients.
  • [MeSH-major] Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Immunoglobulin Light Chains / analysis. Monoclonal Gammopathy of Undetermined Significance / complications. Monoclonal Gammopathy of Undetermined Significance / drug therapy. Nephrotic Syndrome / complications. Nephrotic Syndrome / immunology. Vincristine / administration & dosage
  • [MeSH-minor] Aged. Drug Therapy, Combination. Humans. Male. Remission Induction

  • Genetic Alliance. consumer health - Light chain deposition disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20394211.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Immunoglobulin Light Chains; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin
  •  go-up   go-down


12. Lourenço GJ, Lorand-Metze I, Delamain MT, Miranda EC, Kameo R, Metze K, Lima CS: Polymorphisms of glutathione S-transferase mu 1, theta 1, and pi 1 genes and prognosis in Hodgkin lymphoma. Leuk Lymphoma; 2010 Dec;51(12):2215-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms of glutathione S-transferase mu 1, theta 1, and pi 1 genes and prognosis in Hodgkin lymphoma.
  • We examined the influence of the glutathione S-transferase mu 1 (GSTM1), theta 1 (GSTT1), and pi 1 (GSTP1) polymorphisms, which are involved in the metabolism of alkylating agents and anthracyclines, on the outcome of patients with Hodgkin lymphoma (HL) treated with conventional chemotherapy.
  • Genomic DNA from 125 consecutive cases was analyzed by polymerase chain reaction and enzymatic digestion for polymorphism determination.
  • The GSTM1 undeleted genotype was associated with more advanced tumor stage and worse disease-free survival.
  • In contrast, higher toxicity of chemotherapy was attributed to absence of the GSTT1 gene.
  • [MeSH-major] Glutathione S-Transferase pi / genetics. Glutathione Transferase / genetics. Hodgkin Disease / diagnosis. Hodgkin Disease / genetics. Polymorphism, Genetic


13. Klepstad P, Rakvåg TT, Kaasa S, Holthe M, Dale O, Borchgrevink PC, Baar C, Vikan T, Krokan HE, Skorpen F: The 118 A &gt; G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand; 2004 Nov;48(10):1232-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease.
  • Experimental studies show that morphine and morphine-6-glucuronide are less effective in individuals carrying variant alleles caused by the 118 A > G polymorphism in the mu-opioid receptor gene (OPRM1).
  • METHODS: We screened 207 cancer pain patients on oral morphine treatment for four frequent OPRM1 gene polymorphisms.
  • Patients homozygous for the variant G allele of the 118 A > G polymorphism (n = 4) needed more morphine to achieve pain control, compared to heterozygous (n = 17) and homozygous wild-type (n = 78) individuals.
  • This difference was not explained by other factors such as duration of morphine treatment, performance status, time since diagnosis, time until death, or adverse symptoms.
  • CONCLUSION: Patients homozygous for the 118 G allele of the mu-opioid receptor need higher morphine doses to achieve pain control.
  • Thus, genetic variation at the gene encoding the mu-opioid receptor contributes to variability in patients' responses to morphine.
  • [MeSH-major] Analgesics, Opioid / therapeutic use. Morphine / therapeutic use. Neoplasms / complications. Neoplasms / genetics. Pain, Intractable / drug therapy. Pain, Intractable / genetics. Receptors, Opioid, mu / genetics. Receptors, Opioid, mu / physiology
  • [MeSH-minor] Aged. Alleles. Dose-Response Relationship, Drug. Female. Genetic Testing. Genotype. Humans. Male. Middle Aged. Morphine Derivatives / blood. Pain Measurement / drug effects. Polymorphism, Genetic. Quality of Life. Reverse Transcriptase Polymerase Chain Reaction

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. MORPHINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15504181.001).
  • [ISSN] 0001-5172
  • [Journal-full-title] Acta anaesthesiologica Scandinavica
  • [ISO-abbreviation] Acta Anaesthesiol Scand
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Morphine Derivatives; 0 / OPRM1 protein, human; 0 / Receptors, Opioid, mu; 20290-10-2 / morphine-6-glucuronide; 76I7G6D29C / Morphine; O27Z9CH39A / morphine-3-glucuronide
  •  go-up   go-down


14. Kishore J, Ghoshal U, Ghoshal UC, Krishnani N, Kumar S, Singh M, Ayyagari A: Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome. J Med Microbiol; 2004 Nov;53(Pt 11):1155-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome.
  • Despite frequent use of immunosuppressive drugs in patients with inflammatory bowel disease (IBD) and reports of cytomegalovirus (CMV) infection following post-transplant immunosuppression, data on the frequency and clinical significance of CMV in patients with IBD are scant.
  • Sixty-three patients with IBD (61 ulcerative colitis and two Crohn's disease) were evaluated for CMV using serology (IgM antibody, mu-capture ELISA), PCR for CMV DNA in colonic biopsy and histological assessment of haematoxylin and eosin-stained colonic biopsy.
  • Ten of 63 (15.8 %) patients (age 36.0 +/- 11.2 years, 31 female) were infected with CMV (DNA alone in four, IgM antibody alone in two and both in four, inclusion body in one).
  • Patients with CMV infection more often required surgical treatment for IBD (4/10 vs 4/53, P = 0.01) and had fatal outcome (3/10 vs 0/53, P = 0.003).
  • PCR of rectal biopsy was the most sensitive method of detection followed by IgM antibody for diagnosis.
  • [MeSH-major] Cytomegalovirus / isolation & purification. Cytomegalovirus Infections / complications. Immunosuppressive Agents / therapeutic use. Inflammatory Bowel Diseases / complications. Inflammatory Bowel Diseases / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antibodies, Viral / blood. Azathioprine / therapeutic use. Colon / pathology. Colon / virology. DNA, Viral / analysis. DNA, Viral / genetics. Female. Humans. India. Male. Middle Aged. Polymerase Chain Reaction. Risk Factors

  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15496396.001).
  • [ISSN] 0022-2615
  • [Journal-full-title] Journal of medical microbiology
  • [ISO-abbreviation] J. Med. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / DNA, Viral; 0 / Immunosuppressive Agents; MRK240IY2L / Azathioprine
  •  go-up   go-down


15. Wang J, Huang C, Wei XY, Qi DL, Gong LQ, Mu HY, Yao Q, Li K: Changes of activated circulating endothelial cells and survivin in patients with non-small cell lung cancer after antiangiogenesis therapy. Chin Med J (Engl); 2008 Nov 20;121(22):2234-40
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes of activated circulating endothelial cells and survivin in patients with non-small cell lung cancer after antiangiogenesis therapy.
  • BACKGROUND: Although antiangiogenesis therapy plays an important role in anti-neoplastic treatment with its recognized efficacy and slight adverse effect, there is no prospective clinical trial to define ideal markers for predicting efficacy of antiangiogenic therapy.
  • This study was undertaken to investigate the changes of activated circulating endothelial cells (aCECs) and survivin after anti-angiogenesis therapy and their significance in predicting the efficacy of the therapy.
  • METHODS: Patients of non-small cell lung cancer (NSCLC) treated with chemotherapy with or without Endostar were observed.
  • The amount of activated CECs was detected by flow cytometry, and the expression of survivin mRNA was determined by real-time polymerase chain reaction (PCR).
  • RESULTS: After treatment, the amount of activated CECs decreased significantly in clinical benefit cases (P = 0.021 in chemotherapy alone, P = 0.001 in chemotherapy plus Endostar), increased in disease progressive cases (P = 0.015 in chemotherapy alone, but P = 0.293 in chemotherapy with Endotatar).
  • After therapy, the expression of survivin mRNA decreased in clinical benefit cases (P = 0.001) and increased in disease progressive cases (P = 0.018).
  • A positive correlation was found between activated CECs and survivin in the chemotherapy group pre- and post-therapy (P = 0.001 and 0.021, respectively), but only in the chemotherapy with Endostar group pre-therapy (P = 0.030) rather than post-therapy.
  • A positive correlation was found between the decreased activated CECs after therapy and time to progression (TTP) (r = 0.322, P = 0.012); a negative correlation was found between the amount of survivin mRNA in serum post-therapy and TTP (r = -0.291, P = 0.048).
  • Their combination can evaluate more accurately the efficacy of antiangiogenic therapy of NSCLC.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Endothelial Cells / drug effects. Lung Neoplasms / drug therapy. Microtubule-Associated Proteins / genetics
  • [MeSH-minor] Endostatins / therapeutic use. Female. Flow Cytometry. Gene Expression Regulation, Neoplastic / drug effects. Humans. Immunohistochemistry. Inhibitor of Apoptosis Proteins. Male. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19080323.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / BIRC5 protein, human; 0 / Endostatins; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / endostar protein
  •  go-up   go-down


16. Adam Z, Pour L, Krejcí M, Zahradová L, Krivanová A, Mardová J, Kovárová L, Stepánková S, Moulis M, Kren L, Veselý K, Svobodová I, Germáková Z, Nedbálková M, Mayer J, Hájek R: [Treatment of AL-amyloidosis--results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in AL-amyloidosis]. Vnitr Lek; 2010 Mar;56(3):190-209
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of AL-amyloidosis--results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in AL-amyloidosis].
  • PATIENTS: Fifteen patients with light chain deposits in the form of AL-amyloidosis and 2 patients with light chain deposition as amorphous matter (light chain deposition disease) were treated at our clinic as of 1999.
  • Median age at the diagnosis was 63 (34-77) years.
  • The light chain deposition caused: nephrotic syndrome in 12 (70%) patients, renal insufficiency with reduced filtration in 4 (23%) patients, cardiomyopathy in 4 (23%) patients, hepatosplenomegaly in 2 (12%) patients, manifest coagulopathy in 2 (12%) patients, periorbital hematoma in 2 (12%) patients, visceral and somatic neuropathy in 2 (12%) patients.
  • Treatment with high-dose dexamethasone in combination with adriamycin and vincristine (VAD) or cyclophosphamide (CAD orjust CD) was used in 11 patients.
  • In 4 patients, therapy was completed with high-dose chemotherapy and autologous transplantation; complete haematological and organ treatment response was achieved in all 4 patients with remission lasting 113+, 87+, 50, 45+ months.
  • Of the remaining 7 patients in whom high-dose dexamethasone therapy was not completed with high-dose chemotherapy, 3 achieved complete haematological remission (CR) and very good partial remission (VGPR), with 2 patients achieving complete organ treatment response.
  • PR with no organ treatment response was achieved in other 2 patients and 2 patients died during the treatment.
  • Therapy with prednisone and alkylating cytostatics was used in 2 patients with serious organ damage, both patients died after a short period of time due to the disease and thus treatment response cannot be evaluated.
  • Two patients underwent a total of 5 and 6 cycles of this treatment with PR effect and plateau after the previous decline of monoclonal immunoglobulin concentrations.
  • Treatment combination of bortezomib (Velcade), cyclophosphamide and dexamethasone (VCD) was used in three patients.
  • Just one of the 3 female patients has been followed up for more than 12 months and so it is possible to evaluate organ treatment response in this patient; nephrotic syndrome ceased, meaning that organ CR has been achieved.
  • CONCLUSION: Early diagnosis (before severe organ damage occurs) enables administration of aggressive treatment (high-dose chemotherapy and autologous transplantation) with the outlook of complete haematological and organ treatment response.
  • New drugs thalidomide and bortezomib further expand treatment armamentarium; according to our limited experience and published information, bortezomib may be considered as very effective and well tolerated agent suitable, in combination, for patients with the diagnosis of AL-amyloidosis.
  • [MeSH-major] Amyloidosis / drug therapy. Boronic Acids / administration & dosage. Pyrazines / administration & dosage. Thalidomide / administration & dosage. Thalidomide / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Bortezomib. Drug Therapy, Combination. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20394205.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Pyrazines; 4Z8R6ORS6L / Thalidomide; 69G8BD63PP / Bortezomib; F0P408N6V4 / lenalidomide
  • [Number-of-references] 98
  •  go-up   go-down


17. Liebetrau M, Martens H, Thomassen N, Burggraf D, Gabrijelcic-Geiger D, Lubisch W, Möller A, Hamann GF: Calpain inhibitor A-558693 in experimental focal cerebral ischemia in rats. Neurol Res; 2005 Jul;27(5):466-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied the expression of mu-calpain in a model of focal cerebral ischemia/reperfusion and the efficacy of the calpain inhibitor A-558693.
  • Furthermore mu-calpain positive-stained cells were detected by immunohistochemistry and western blotting.
  • RESULTS: In placebo-treated animals the mu-calpain expression was significantly increased in the ischemic hemisphere compared with the contralateral non-ischemic hemisphere (88.6 versus 10.5% in the basal ganglia, 60.7 versus 10.7% in the cortex, p < 0.001, respectively) with a subsequent loss its substrate MAP-2.
  • However, the use of the calpain inhibitor A-558693 did not significantly change the mu-calpain expression, nor significantly reduce the infarct volume.
  • DISCUSSION: The present data indicate that mu-calpain proteolysis plays an important role in the chain of events following cerebral ischemia.
  • [MeSH-major] Brain Infarction / prevention & control. Brain Ischemia / drug therapy. Calpain / antagonists & inhibitors. Disease Models, Animal. Enzyme Inhibitors / therapeutic use
  • [MeSH-minor] Amides / therapeutic use. Animals. Blotting, Western / methods. Cell Count / methods. Gene Expression Regulation / drug effects. Immunohistochemistry / methods. Infarction, Middle Cerebral Artery / complications. Male. Rats. Rats, Wistar. Reperfusion Injury / metabolism. Reperfusion Injury / pathology. Reperfusion Injury / prevention & control

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15978171.001).
  • [ISSN] 0161-6412
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / A-558693; 0 / Amides; 0 / Enzyme Inhibitors; EC 3.4.22.- / Calpain; EC 3.4.22.- / mu-calpain
  •  go-up   go-down


18. Zhong SL, Zhou S, Chen X, Huang M: Rapid determination of common mutations in glutathione S-transferase gene by PCR-based methods in healthy Chinese. Clin Chim Acta; 2006 Feb;364(1-2):205-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All these mutations, in particular those in class mu, pi and theta GST, are likely to contribute to interindividual differences in responses to xenobiotics including response to chemotherapy and associated with altered disease.
  • [MeSH-major] Glutathione Transferase / genetics. Mutation. Polymerase Chain Reaction / methods

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Chim Acta. 2006 Aug;370(1-2):203 [16814272.001]
  • (PMID = 16098500.001).
  • [ISSN] 0009-8981
  • [Journal-full-title] Clinica chimica acta; international journal of clinical chemistry
  • [ISO-abbreviation] Clin. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 9007-49-2 / DNA; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


19. Gürsoy M, Gür G, Arslan H, Ozdemir N, Boyacioglu S: Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment. J Viral Hepat; 2001 Jan;8(1):70-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment.
  • In view of the high rate of chronicity of acute hepatitis C and the low efficacy of interferon (IFN) treatment in advanced liver disease, it may be beneficial to treat patients during the acute phase of the infection.
  • Here we assessed the effects of variable-dose IFNalpha-2b treatment in haemodialysis patients with acute hepatitis C virus (HCV) infection, and identified factors that may predict response to this therapy.
  • Seventeen patients who received no specific treatment were used as controls (Group 1).
  • Sixteen and 20 patients received low-(3 MU) and high-dose (6-10 MU) IFNalpha-2b three times weekly for 3 months (Groups 2 and 3, respectively).
  • Virological end-of-treatment response (ETR) was observed in 1 (5.6%), 13 (56.5%), and 17 (65.4%) patients in Groups 1, 2, and 3, respectively, and virological sustained response (SR) was observed in 1 (5.6%), 6 (26.1%), and 13 (50%) patients in the three groups.
  • In conclusion, IFN-alpha treatment initiated during the acute phase of HCV infection is associated with a higher rate of virological ETR and SR.
  • [MeSH-major] Antiviral Agents / therapeutic use. Hepacivirus / genetics. Hepatitis C / drug therapy. Interferon-alpha / therapeutic use. Renal Dialysis
  • [MeSH-minor] 5' Untranslated Regions / genetics. Acute Disease. Adult. Female. Genotype. Humans. Male. Middle Aged. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Predictive Value of Tests. RNA, Viral / blood. Recombinant Proteins. Treatment Outcome. Viral Envelope Proteins / genetics

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11155154.001).
  • [ISSN] 1352-0504
  • [Journal-full-title] Journal of viral hepatitis
  • [ISO-abbreviation] J. Viral Hepat.
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 5' Untranslated Regions; 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / RNA, Viral; 0 / Recombinant Proteins; 0 / Viral Envelope Proteins; 157184-61-7 / glycoprotein E2, Hepatitis C virus; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


20. Mazzaro C, Panarello G, Carniello S, Faelli A, Mazzi G, Crovatto M, Baracetti S, Nascimben F, Zorat F, Pozzato G, Faccini L, Campanacci L: Interferon versus steroids in patients with hepatitis C virus-associated cryoglobulinaemic glomerulonephritis. Dig Liver Dis; 2000 Nov;32(8):708-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The renal disease had usually been treated with immunosuppressive therapy, but, given the presence of viral infection, this therapy is no longer recommended.
  • In this study, we compare steroid vs interferon therapy in a group of patients affected by hepatitis C virus-positive cryoglobulinaemic glomerulonephritis in the stationary phase.
  • PATIENTS/METHODS: The diagnosis of cryoglobulinaemic glomerulonephritis was made bearing in mind standard criteria.
  • Patients were randomly assigned to 2 groups receiving oral prednisone 0.2 mg/kg/die for 6 months (6 patients, group A) or lymphoblastoid interferon 3 MU, three times a week for 6 months [7 patients, group B).
  • Hepatitis C virus-RNA was determined by reverse transcription-polymerase chain reaction and hepatitis C virus genotype according to Okamoto.
  • Hepatitis C virus-RNA quantitation was performed by competitive polymerase chain reaction.
  • All genotypes of hepatitis C virus were found with a prevalence of Type 1b.
  • At the end of the treatment, all patients in both groups relapsed.
  • CONCLUSIONS: Interferon seems to be an effective drug in the treatment of cryoglobulinaemic glomerulonephritis, but dosage and length of treatment still need to be addressed by large multicentre studies.
  • [MeSH-major] Anti-Inflammatory Agents / therapeutic use. Antiviral Agents / therapeutic use. Cryoglobulinemia / drug therapy. Cryoglobulinemia / virology. Glomerulonephritis / drug therapy. Glomerulonephritis / virology. Hepatitis C / complications. Interferon-alpha / therapeutic use. Prednisone / therapeutic use
  • [MeSH-minor] Aged. Female. Genotype. Hepacivirus / genetics. Humans. Immunophenotyping. Male. Middle Aged. Prospective Studies. RNA, Viral / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Glomerulonephritis.
  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11142582.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / RNA, Viral; VB0R961HZT / Prednisone
  •  go-up   go-down


21. Berasain C, Sampedro A, Mauleón I, Goñi S, Latasa MU, Matscheko N, García-Bravo M, Unzu C, Corrales FJ, Enríquez de Salamanca R, Prieto J, Avila MA, Fontanellas A: Epidermal growth factor receptor ligands in murine models for erythropoietic protoporphyria: potential novel players in the progression of liver injury. Cell Mol Biol (Noisy-le-grand); 2009;55(1):29-37
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However its chronic activation participates in the progression of liver disease, including fibrogenesis and malignant transformation.
  • Hepatobiliary disease represents a constant feature in the clinically relevant Fechm1pas/Fechm1pas genetic model of erythropoietic protoporphyria (EPP).
  • Our findings suggest that protoporphyrin could directly induce the hepatic expression of EGFR ligands, and that their chronic upregulation might participate in the pathogenesis of EPP-associated liver disease.
  • [MeSH-major] Liver / drug effects. Liver / metabolism. Protoporphyria, Erythropoietic / metabolism. Receptor, Epidermal Growth Factor / agonists. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Amphiregulin. Animals. Betacellulin. Cell Line. EGF Family of Proteins. Epidermal Growth Factor / genetics. Epigen. Epiregulin. Glycoproteins / genetics. Griseofulvin / pharmacology. Heparin-binding EGF-like Growth Factor. Intercellular Signaling Peptides and Proteins / genetics. Liver Diseases / genetics. Liver Diseases / metabolism. Male. Mice. Mice, Inbred C57BL. Mice, Mutant Strains. Protoporphyrins / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transforming Growth Factor alpha / genetics

  • Hazardous Substances Data Bank. GRISEOFULVIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19267999.001).
  • [ISSN] 1165-158X
  • [Journal-full-title] Cellular and molecular biology (Noisy-le-Grand, France)
  • [ISO-abbreviation] Cell. Mol. Biol. (Noisy-le-grand)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Amphiregulin; 0 / Areg protein, mouse; 0 / Betacellulin; 0 / Btc protein, mouse; 0 / EGF Family of Proteins; 0 / Epgn protein, mouse; 0 / Epigen; 0 / Epiregulin; 0 / Ereg protein, mouse; 0 / Glycoproteins; 0 / Hbegf protein, mouse; 0 / Heparin-binding EGF-like Growth Factor; 0 / Intercellular Signaling Peptides and Proteins; 0 / Protoporphyrins; 0 / Transforming Growth Factor alpha; 32HRV3E3D5 / Griseofulvin; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


22. Cheng PN, Chow NH, Hu SC, Young KC, Chen CY, Jen CM, Chang TT: Clinical comparison of high-dose interferon-alpha2b with or without ribavirin for treatment of interferon-relapsed chronic hepatitis C. Dig Liver Dis; 2002 Dec;34(12):851-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical comparison of high-dose interferon-alpha2b with or without ribavirin for treatment of interferon-relapsed chronic hepatitis C.
  • BACKGROUND: Interferon a with ribavirin combination therapy is effective but still unsatisfactory in the treatment of patients with interferon-relapsed chronic hepatitis C.
  • AIMS: To compare, in a randomized, double blind, placebo-controlled study, high-dose interferon-alpha2b with or without ribavirin in the treatment for interferon-relapsers.
  • PATIENTS: A total of 52 patients with interferon-relapsed chronic hepatitis C were randomly assigned to receive 24-week treatment with interferon-alpha2b (6 MU three times per week) combined with either ribavirin (1,000 to 1,200 mg per day) or a matched placebo and then followed for an additional 24 weeks.
  • METHODS: Hepatitis C virus RNA was detected by reverse-transcription polymerase chain reaction.
  • Genotyping was performed by reverse hybridization assay RESULTS: At the end of treatment, no detectable hepatitis C virus RNA levels were observed in 92% (24/26) of patients on interferon alpha2b/ribavirin and 81% (21/26) of patients on interferon alpha2b/placebo.
  • Patients who received interferon-alpha2b/ribavirin treatment and in whom no hepatitis C virus RNA was detected at 4th week after treatment had 90% chance to achieve sustained virological response.
  • CONCLUSIONS: High-dose interferon-alpha2b plus ribavirin treatment is highly effective in interferon-relapsed patients.
  • [MeSH-major] Antiviral Agents / administration & dosage. Hepatitis C, Chronic / drug therapy. Interferon-alpha / administration & dosage. Ribavirin / administration & dosage
  • [MeSH-minor] Adult. Double-Blind Method. Drug Administration Schedule. Drug Therapy, Combination. Female. Hepacivirus / genetics. Humans. Male. Middle Aged. RNA, Viral / analysis. Recurrence

  • Genetic Alliance. consumer health - Hepatitis.
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12643293.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / RNA, Viral; 49717AWG6K / Ribavirin
  •  go-up   go-down


23. Aziz S, Qamar R, Ahmed I, Imran K, Masroor M, Rajper J, Nafay S, Noorulain W, Khan MH: Treatment profile of hepatitis C patients - a comparison of interferon alpha 2a and 2b treatment regimes. J Coll Physicians Surg Pak; 2010 Sep;20(9):581-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment profile of hepatitis C patients - a comparison of interferon alpha 2a and 2b treatment regimes.
  • OBJECTIVE: To compare the side effects, cost, end treatment response (ETR) and Sustained viral response (SVR) with combination therapy of either interferon alpha 2a or 2b in combination with Ribavarin.
  • METHODOLOGY: Patients positive for qualitative HCV ribonucleic acid (RNA) by Polymerase chain reaction (PCR) and genotype 3 were included.
  • Patients with decompensated cirrhosis, severe depressive illness, autoimmune hepatitis, hyperthyroidism, pregnancy, heart failure, uncontrolled diabetes, obstructive pulmonary disease, children less than three years and patients who had previously received treatment were excluded.
  • Single blind randomization using computerized randomization list was done and patients divided into groups A and B, those requiring treatment were given injection Interferon 3 million units (MU) subcutaneously (SC) three times/week and Ribavarin 1000 mg per day (weight ≤ 75kg) and 1200 mg/day (weight > 75kg) orally with either interferon alpha 2a (group A; FDA approved products) or alpha 2b (group B; non FDA approved product).
  • ETR was defined as absence of virus at the end of treatment and SVR was taken as absence of HCV RNA at 6 months after completion of treatment.
  • The cost of treatment for interferon alpha for a single patient for 6 months was Rs 60,000, while for Interferon alpha 2b was Rs 30,000.
  • CONCLUSION: Response to combination therapy for HCV was 83%.
  • [MeSH-major] Antiviral Agents / therapeutic use. Hepatitis C, Chronic / drug therapy. Interferon-alpha / therapeutic use

  • Genetic Alliance. consumer health - Hepatitis.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Coll Physicians Surg Pak. 2012 Jan;22(1):70-1; author reply 71 [22237201.001]
  • (PMID = 20810048.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


24. Mousa DH, Abdalla AH, Al-Shoail G, Al-Sulaiman MH, Al-Hawas FA, Al-Khader AA: Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc; 2004 Jul-Aug;36(6):1831-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C.
  • INTRODUCTION: Hepatitis C Viral (HCV) infection is the leading cause of chronic liver disease in end-stage renal disease patients (ESRD).
  • The main aim of this pilot study was to assess the efficacy of combined alpha-interferon (alpha-IFN) and ribavirin treatment of HCV hemodialysis (HDx) patients, by comparing the sustained virological response to that obtained by local historical data on treatment with alpha-IFN alone.
  • A secondary aim was to establish the optimal therapeutic dose of ribavirin in this regimen.
  • They received combination therapy with 3 million units (MU) of alpha-IFN and 200 mg of ribavirin three times a week.
  • RESULTS: Six of the nine patients who were treated for 24 weeks (66%) became HCV-PCR-negative by the end of the treatment period.
  • They continued to have a sustain virologic response at 6 months after the cessation of therapy.
  • Six of the 11 patients (55%) who were treated for 48 weeks became HCV-PCR-negative at the end, and at 6 months after cessation of treatment.
  • Of the first six responders, 4 (66%) maintained a sustained virologic response at 1 year postcessation of therapy.
  • No side effects were reported for a ribavirin dose of 200 mg three times a week.
  • CONCLUSION: This pilot study suggests that combination treatment for 24 weeks and 48 weeks with 3 MU alpha-IFN and 200 mg ribavirin three times a week, elicited a sustained virologic response in HDx patients with HCV infection better than IFN alone with minimal side effects.
  • [MeSH-major] Antiviral Agents / therapeutic use. Hepatitis C / drug therapy. Interferon-alpha / therapeutic use. Renal Dialysis / adverse effects. Ribavirin / therapeutic use
  • [MeSH-minor] Adult. Aged. Drug Therapy, Combination. Female. Hepacivirus / genetics. Hepacivirus / isolation & purification. Humans. Male. Middle Aged. Pilot Projects. Polymerase Chain Reaction. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15350490.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 49717AWG6K / Ribavirin
  •  go-up   go-down


25. Casanovas-Taltavull T, Baliellas C, Benasco C, Serrano TT, Casanova A, Pérez JL, Guerrero L, González MT, Andres E, Gil-Vernet S, Casais LA: Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. Am J Gastroenterol; 2001 Apr;96(4):1170-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to evaluate IFN treatment in kidney transplant candidates during the hemodialysis period as well as the results after transplantation.
  • METHODS: A total of 29 noncirrhotic hemodialysis patients with chronic hepatitis C virus (HCV) infection (based on long-term rise in ALT, HCV serology, HCV RNA by polymerase chain reaction methods, and histological evidence) were included.
  • Tolerability to IFN treatment, pre- and posttransplantation therapeutic results, and long-term outcome were recorded.
  • IFN regimen consisted of 3 million units (MU) times per week after hemodialysis sessions for 6 months, followed by 1.5 MU after each hemodialysis session for an additional 6 months.
  • RESULTS: IFN therapy was fairly well tolerated.
  • Adverse effects due to IFN toxicity, renal disease, or causes related to the immunological properties of IFN were observed in 24% of patients.
  • At the end of treatment, ALT had normalized in 23/28 patients (82.1%), and HCV RNA had cleared in 23/28 patients (82.1%).
  • Mean follow-up after the procedure was 41 +/- 28 months.
  • CONCLUSIONS: Treatment results in our study population were better than those observed in the general population.
  • [MeSH-major] Antiviral Agents / therapeutic use. Hepatitis C, Chronic / complications. Hepatitis C, Chronic / drug therapy. Interferon-alpha / therapeutic use. Kidney Failure, Chronic / complications. Kidney Failure, Chronic / surgery. Kidney Transplantation. Preoperative Care


26. Wang M, Liu R, Jia X, Mu S, Xie R: N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal inflammation and tubulointerstitial fibrosis in rats. Int J Mol Med; 2010 Dec;26(6):795-801
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Renal macrophage infiltration, together with protein expression and localization of monocyte chemoattractant protein-1 (MCP-1), nuclear factor-kappa B (NF-κB), α-smooth muscle actin (α-SMA) and transforming growth factor-β1 (TGF-β1) in renal tissue was assessed by immunohistochemical staining.
  • Gene expression of MCP-1 and TGF-β1 was analyzed with reverse transcription-polymerase chain reaction.
  • ED-1 was expressed in the interstitium of the UUO/vehicle group kidneys and decreased with Ac-SDKP treatment.
  • [MeSH-major] Fibrosis / drug therapy. Kidney Tubules / pathology. Nephritis / drug therapy. Oligopeptides / pharmacology
  • [MeSH-minor] Animals. Biomarkers / metabolism. Disease Models, Animal. Histocytochemistry. Intercellular Signaling Peptides and Proteins / genetics. Intercellular Signaling Peptides and Proteins / metabolism. Macrophages / metabolism. Male. Rats. Rats, Wistar

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21042772.001).
  • [ISSN] 1791-244X
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Intercellular Signaling Peptides and Proteins; 0 / Oligopeptides; H041538E9P / goralatide
  •  go-up   go-down


27. Safwat A, Schmidt H, Bastholt L, Fode K, Larsen S, Aggerholm N, von der Maase H: A phase II trial of low-dose total body irradiation and subcutaneous interleukin-2 in metastatic melanoma. Radiother Oncol; 2005 Nov;77(2):143-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: Our own experimental data suggests a therapeutic synergism between low-dose total body irradiation (LTBI) and interleukin-2 (IL-2).
  • One treatment cycle included 5 weeks treatment followed by 2 weeks break and composed of a single radiation fraction 0.1 Gy on days 1, 8, 22 and 30 and IL-2: 18 MU x 2 daily s.c. on days 2 to 5 and days 16-19 as well as 9 MU x 2 daily s.c. on days 9-12 and 31-34.
  • In 17 patients, flow cytometric analyses of the various subpopulations of immune cells were done on blood samples before the first LTBI fraction and 24h after LTBI as well as after the first week of treatment.
  • RESULTS: Two patients (4.4%) had a partial response (PR) and 13 patients (29%) had stable disease (SD).
  • The duration of the partial remission and stable disease did not exceed 3 months.
  • Thirty-four of the 58 treatment cycles (74%) were given in 100% of the intended dose without modification or delay.
  • There were no treatment-related deaths.
  • Flowcytometry data showed a significant increase in the percentage of cells carrying the beta chain of IL-2 receptor (CD122+), a significant increase in the percentage of NK cells (CD56+ cells) as well as a significant reduction in the percentage of B cells (CD20+) and monocytes (CD14+).
  • [MeSH-major] Interleukin-2 / therapeutic use. Melanoma / secondary. Melanoma / therapy. Skin Neoplasms / pathology. Skin Neoplasms / therapy. Whole-Body Irradiation / methods
  • [MeSH-minor] Adult. Aged. Denmark. Dose-Response Relationship, Drug. Dose-Response Relationship, Radiation. Female. Flow Cytometry. Follow-Up Studies. Humans. Injections, Subcutaneous. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Radiotherapy Dosage. Risk Assessment. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16216360.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Interleukin-2
  •  go-up   go-down


28. Macedo G, Correia A, Ribeiro T: Antiviral treatment in acute hepatitis C. Hepatogastroenterology; 2003 Jul-Aug;50(52):1057-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiviral treatment in acute hepatitis C.
  • BACKGROUND/AIMS: Several treatment schedules have been tried in acute hepatitis C, but due to the heterogeneity of included patients and to the non-practical interferon protocols, we assessed prospectively in a non-randomized pilot study, the efficacy of interferon 2b.
  • METHODOLOGY: Five million units of interferon 2b were given three times weekly by subcutaneous route for 6 months as soon as diagnosis of acute hepatitis C was established.
  • Interferon was very well tolerated and there was no need for changing treatment schedule.
  • CONCLUSIONS: These findings suggest that 5 MU TIW for 6 months is well tolerated and effective in preventing, in a non-aggressive way, a chronic course of hepatitis C infection.
  • [MeSH-major] Antiviral Agents / therapeutic use. Hepatitis C / drug therapy. Interferon-alpha / therapeutic use
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Female. Hepacivirus / genetics. Humans. Injections, Subcutaneous. Male. Middle Aged. Pilot Projects. Polymerase Chain Reaction. Prospective Studies. RNA, Viral / analysis. Recombinant Proteins

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12845981.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / RNA, Viral; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


29. Lindman AS, Pedersen JI, Hjerkinn EM, Arnesen H, Veierød MB, Ellingsen I, Seljeflot I: The effects of long-term diet and omega-3 fatty acid supplementation on coagulation factor VII and serum phospholipids with special emphasis on the R353Q polymorphism of the FVII gene. Thromb Haemost; 2004 Jun;91(6):1097-104
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the present study was to investigate the effect of long-term diet and very long chain n-3 fatty acids (VLC n-3) intervention on plasma coagulation factor VII (FVII), choline-containing phospholipids (PC) and triglycerides (TG), especially related to the R353Q polymorphism of the FVII gene.
  • The subjects were randomly allocated to receive placebo capsules (corn oil) (control), placebo capsules and dietary advice ("Mediterranean type" diet), VLC n-3 capsules, or VLC n-3 capsules and dietary advice combined.
  • Diet intervention was followed by a significant reduction of 5.1% in the levels of FVIIag and 2.4 mU/ml in FVIIa (95% CI -7.4, -2.9, and -3.8, -1.1, respectively) (both p<0.001) compared to the no diet group, independent of genotype.
  • Dietary advice towards a "Mediterranean type" diet, but not VLC n-3 supplementation, was shown to reduce the levels of FVIIag and FVIIa after 6 months, independent of genotype.
  • [MeSH-major] Dietary Supplements. Factor VII / drug effects. Factor VII / genetics. Fatty Acids, Omega-3 / pharmacology. Phospholipids / blood. Polymorphism, Single Nucleotide
  • [MeSH-minor] Aged. Arteriosclerosis / drug therapy. Coronary Disease / prevention & control. Humans. Male. Mutation, Missense. Phosphatidylcholines / blood. Risk. Triglycerides / blood

  • MedlinePlus Health Information. consumer health - Dietary Supplements.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15175795.001).
  • [ISSN] 0340-6245
  • [Journal-full-title] Thrombosis and haemostasis
  • [ISO-abbreviation] Thromb. Haemost.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Fatty Acids, Omega-3; 0 / Phosphatidylcholines; 0 / Phospholipids; 0 / Triglycerides; 9001-25-6 / Factor VII
  •  go-up   go-down


30. Sobesky R, Buffet C: [Management of patients infected with hepatitis C virus]. Presse Med; 2001 Apr 14;30(14):667-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Prise en charge des patients infectés par le virus de l'hépatite C.
  • Careful management is required since about 75% of all infected subjects will develop chronic liver disease with the risk of progression to cirrhosis.
  • The major improvements in the efficacy of treatments developed over the last decade should help reduce the incidence of cirrhosis-related complications.
  • An antiviral treatment should be prescribed for patients free of decompensated cirrhosis or contraindications who have moderate to severe histological lesions.
  • STANDARD TREATMENT: Alpha-interferon (3 MU three times a week) in combination with ribavirin (1000-1200 mg/d) should be given for 6 to 12 months.
  • This new interferon, given in association with ribavirin, will undoubtedly shortly become the gold standard treatment for patients with chronic hepatitis C, particularly those infected with treatment-resistant geno-types.
  • [MeSH-major] Hepatitis C / drug therapy
  • [MeSH-minor] Hepacivirus / genetics. Humans. Liver Cirrhosis / virology. Polymerase Chain Reaction. RNA, Viral / blood. Transaminases / blood

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11360728.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / RNA, Viral; EC 2.6.1.- / Transaminases
  • [Number-of-references] 37
  •  go-up   go-down


31. Sacharczuk M, Lesniak A, Korostynski M, Przewlocki R, Lipkowski A, Jaszczak K, Sadowski B: A polymorphism in exon 2 of the delta-opioid receptor affects nociception in response to specific agonists and antagonists in mice selectively bred for high and low analgesia. Pain; 2010 Jun;149(3):506-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study searched for polymorphic sites in the murine mu-, delta- and kappa-opioid receptors that presumably influence pain perception.
  • We found a novel C320T transition in exon 2 of the delta-opioid receptor gene, resulting in an A107V substitution in the first extracellular loop (EL1) of the peptide chain.
  • Moreover, this transition affects the pharmacological effects of two specific delta-opioid receptor ligands, the agonist SNC80 and the antagonist naltrindole.
  • [MeSH-major] Genetic Predisposition to Disease / genetics. Nociceptors / drug effects. Nociceptors / metabolism. Pain / drug therapy. Pain / genetics. Polymorphism, Genetic / drug effects. Polymorphism, Genetic / genetics. Receptors, Opioid, delta / genetics
  • [MeSH-minor] Animals. Disease Models, Animal. Exons / drug effects. Exons / genetics. Gene Expression Regulation / drug effects. Male. Mice. Mice, Neurologic Mutants. Narcotic Antagonists / pharmacology. Narcotics / pharmacology. Rats

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20381245.001).
  • [ISSN] 1872-6623
  • [Journal-full-title] Pain
  • [ISO-abbreviation] Pain
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Narcotic Antagonists; 0 / Narcotics; 0 / Receptors, Opioid, delta
  •  go-up   go-down


32. Reddy PJ, Aksoy MO, Yang Y, Li XX, Ji R, Kelsen SG: Inhibition by salmeterol and cilomilast of fluticasone-enhanced IP-10 release in airway epithelial cells. COPD; 2008 Feb;5(1):5-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The CXC chemokines, IP-10/CXCL10 and IL-8/CXCL8, play a role in obstructive lung disease by attracting Th1/Tc1 lymphocytes and neutrophils, respectively.
  • Cytokine treatment (TNF-alpha, IL-1beta and IFN-gamma) increased IP-10 and IL-8 protein and mRNA levels.
  • Fluticasone (0.1 nM to 1 microM) increased IP-10 but reduced IL-8 protein release without changing IP-10 mRNA levels assessed by real time RT-PCR.
  • The combination of salmeterol (1 micro M) and cilomilast (1-10 mu M) reduced IP-10 but had no effect on IL-8 protein.
  • In human airway epithelial cells, inhibition by salmeterol of fluticasone-enhanced IP-10 release may be an important therapeutic effect of the LABA/ICS combination not present when the two drugs are used separately.
  • [MeSH-major] Albuterol / analogs & derivatives. Chemokine CXCL10 / antagonists & inhibitors. Epithelial Cells / metabolism. Gene Expression / drug effects. Nitriles / pharmacology. RNA / genetics. Respiratory Mucosa / pathology
  • [MeSH-minor] Adrenergic beta-Agonists / pharmacology. Asthma / drug therapy. Asthma / metabolism. Asthma / pathology. Carboxylic Acids / pharmacology. Cells, Cultured. Cyclohexanecarboxylic Acids. Enzyme-Linked Immunosorbent Assay. Humans. Interleukin-8 / antagonists & inhibitors. Interleukin-8 / biosynthesis. Interleukin-8 / genetics. Phosphodiesterase Inhibitors. Reverse Transcriptase Polymerase Chain Reaction. Salmeterol Xinafoate

  • Hazardous Substances Data Bank. ALBUTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18259970.001).
  • [ISSN] 1541-2555
  • [Journal-full-title] COPD
  • [ISO-abbreviation] COPD
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic beta-Agonists; 0 / Carboxylic Acids; 0 / Chemokine CXCL10; 0 / Cyclohexanecarboxylic Acids; 0 / Interleukin-8; 0 / Nitriles; 0 / Phosphodiesterase Inhibitors; 63231-63-0 / RNA; 6EW8Q962A5 / Salmeterol Xinafoate; 8ATB1C1R6X / Cilomilast; QF8SVZ843E / Albuterol
  •  go-up   go-down


33. Boucher E, Guyader D, Jacquelinet S, Andre P, Mendler MH, Turlin B, Canva V, Nousbaum JB, Bernard PH, Nouel O, Raabe JJ, Dao T, Gasser P, Verger P, Boutin J, Bergerault P, Joram F, Colmar P, Messner M, Brissot P, Deugnier Y: Interferon and ursodeoxycholic acid combined therapy in chronic viral C hepatitis: controlled randomized trial in 203 patients. Dig Liver Dis; 2000 Jan-Feb;32(1):29-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon and ursodeoxycholic acid combined therapy in chronic viral C hepatitis: controlled randomized trial in 203 patients.
  • They were all given: interferon alpha-2a (3 MU subcutaneously thrice a week) and ursodeoxycholic acid (10 mg/kg/day) for 9 months.
  • At month 9, biochemical responders only were randomized into ursodeoxycholic acid treatment or placebo for 12 additional months (double blind study).
  • RESULTS: At the end of interferon therapy, 71 patients (37%) were virological responders and 107 (56%) patients were biochemical responders and were randomized: 54 into the ursodeoxycholic acid group and 53 into the placebo group.
  • CONCLUSION: Continuation of ursodeoxycholic acid therapy after withdrawal of interferon in patients with end-of-treatment response did not result in any significant improvement either in the maintenance of response to interferon or in liver histology.
  • [MeSH-major] Antiviral Agents / therapeutic use. Cholagogues and Choleretics / therapeutic use. Hepatitis C, Chronic / drug therapy. Interferon-alpha / therapeutic use. Ursodeoxycholic Acid / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy. Double-Blind Method. Drug Therapy, Combination. Enzyme-Linked Immunosorbent Assay. Female. Hepacivirus / genetics. Hepacivirus / immunology. Hepatitis C Antibodies / analysis. Humans. Male. Middle Aged. Prospective Studies. RNA, Viral / analysis. Recombinant Proteins. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10975752.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] ITALY
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Cholagogues and Choleretics; 0 / Hepatitis C Antibodies; 0 / Interferon-alpha; 0 / RNA, Viral; 0 / Recombinant Proteins; 724L30Y2QR / Ursodeoxycholic Acid; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


34. Lampertico P, Del Ninno E, Viganò M, Romeo R, Donato MF, Sablon E, Morabito A, Colombo M: Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology; 2003 Apr;37(4):756-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy.
  • To assess whether extended treatment with interferon improves the outcome of hepatitis B e antigen (HBeAg)-negative chronic hepatitis B, 101 consecutive patients were treated with 6 MU of interferon alfa 2b 3 times weekly for 24 months.
  • During the 68-month study, 30 patients (30%) had a sustained response (i.e., normal serum transaminase levels and undetectable hepatitis B virus DNA by non-polymerase chain reaction [PCR] assays), and 15 cleared serum surface antigen.
  • Twenty-five nonresponders, 16 relapsers, and 30 who discontinued treatment were considered treatment failures.
  • Multivariate analysis predicted a sustained response for young age (odds ratio, 0.94; 95% confidence interval, 0.89-0.99; P =.041) and high pretreatment serum levels of immunoglobulin M (IgM) anti-hepatitis B core antigen (HBc) (odds ratio, 4.52; 95% confidence interval, 1.63-12.5; P =.004).
  • Liver disease progressed in none of the sustained responders but in 16 with treatment failure (0% vs. 22%, P =.002); hepatocellular carcinoma (HCC) developed with similar frequency in both groups (7%).
  • Overall, estimated 8-year complication-free survival was longer for the 30 sustained responders than the 71 patients with treatment failure (90% vs. 60%, P <.001), but 8-year patient survival was similar in the 2 groups (100% and 90%).
  • In conclusion, 24 months of treatment with interferon alfa 2b led to sustained disease suppression in a significant proportion of patients with HBeAg-negative chronic hepatitis B.
  • [MeSH-major] Antiviral Agents / administration & dosage. Hepatitis B e Antigens / analysis. Hepatitis B, Chronic / drug therapy. Hepatitis B, Chronic / immunology. Interferon-alpha / administration & dosage
  • [MeSH-minor] Adult. Alanine Transaminase / blood. Cohort Studies. DNA, Viral / metabolism. Drug Administration Schedule. Female. Follow-Up Studies. Hepatitis B virus / genetics. Humans. Liver / pathology. Male. Middle Aged. Recombinant Proteins. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Hepatitis E.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hepatology. 2003 Sep;38(3):779-80; author reply 780 [12939609.001]
  • (PMID = 12668967.001).
  • [ISSN] 0270-9139
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / DNA, Viral; 0 / Hepatitis B e Antigens; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


35. Villa E, Grottola A, Buttafoco P, Colantoni A, Bagni A, Ferretti I, Cremonini C, Bertani H, Manenti F: High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial. Am J Gastroenterol; 2001 Oct;96(10):2973-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Coinfection with hepatitis B (HBV) and hepatitis C (HCV) viruses is associated with a more severe liver disease, increased frequency in the development of hepatocellular carcinoma, and resistance to interferon (IFN) therapy when performed with the standard dosages used in single infections.
  • In the attempt to verify whether the outcome of IFN therapy in patients with hepatitis B and hepatitis C coinfection can be improved, we have planned a prospective, randomized trial with medium to high dosages of interferon three times a week for 6 months.
  • METHODS: Thirty patients with HBV-HCV coinfection, and chronic hepatitis were randomized to receive either 6 or 9 MU alpha-interferon three times a week for 6 months.
  • Patients were HBsAg positive, anti-HBe positive, HBV DNA negative by dot blot (6/30 positive by polymerase chain reaction), and anti-HCV-positive, HCV RNA positive.
  • RESULTS: Five patients treated with 9 MU IFN consistently cleared HCV RNA and HBV DNA, whereas none of those treated with 6 MU reacted in a similar fashion (p = 0.045).
  • Long term follow-up showed that none of the patients treated with high doses developed cirrhosis whereas 4/14 treated with low doses did develop cirrhosis.
  • [MeSH-major] Antiviral Agents / therapeutic use. Hepatitis B, Chronic / complications. Hepatitis B, Chronic / drug therapy. Hepatitis C, Chronic / complications. Hepatitis C, Chronic / drug therapy. Interferon-alpha / therapeutic use
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Prospective Studies

  • Genetic Alliance. consumer health - Hepatitis.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11693335.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha
  •  go-up   go-down


36. Zylberberg H, Benhamou Y, Lagneaux JL, Landau A, Chaix ML, Fontaine H, Bochet M, Poynard T, Katlama C, Pialoux G, Bréchot C, Pol S: Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut; 2000 Nov;47(5):694-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.
  • BACKGROUND: More severe liver disease together with a poor response rate to alpha interferon argue for the use of more potent anti-hepatitis C virus (HCV) therapies in human immunodeficiency virus (HIV)-HCV coinfected patients, but the efficacy and safety of interferon-ribavirin combination therapy in HIV infected subjects are unknown.
  • AIM: To retrospectively evaluate the efficacy and safety of anti-HCV combination therapy in 21 HCV-HIV coinfected patients receiving antiretroviral therapy, and to access the clinical relevance of in vitro inhibition of phosphorylation by ribavirin of potent inhibitors of HIV-that is, zidovudine, stavudine, and zalcitabine.
  • PATIENTS: Twenty one patients were treated with combined antiretroviral therapy including zidovudine (n=8) or stavudine (n=13) (in association with protease inhibitors in 12).
  • All received ribavirin (1000 or 1200 mg/day) and alpha interferon (3 MU three times/week) for chronic hepatitis C infection.
  • All patients had not responded (n=20) or relapsed (n=1) after a previous six month course of alpha interferon therapy.
  • METHODS: HIV viral load (Monitor test) and CD4 cells count were measured at the beginning and every three months during and after ribavirin plus alpha interferon therapy over a mean period of 11 (1) months.
  • RESULTS: There was no significant variation in HIV viral load or CD4 cell counts after three or six months of ribavirin therapy compared with baseline values.
  • Eleven of 21 (52.4%) had initial negative HCV viraemia at three (n=10) or six (n=1) months but only six were polymerase chain reaction negative at the end of therapy, leading to rates for primary response and breakthrough of 23.8% and 28.5%, respectively.
  • Six months after completion of therapy, three patients relapsed (14.
  • Median haemoglobin concentration decreased significantly after three and six months of ribavirin therapy (p= 0.0002 and p=0.0003, respectively) leading to withdrawal of therapy in one patient.
  • (2) alpha interferon and ribavirin combination therapy induced primary and sustained virological responses in 28.5% and 14.3% of treated subjects (who were previous non-responders to interferon therapy), respectively;.
  • [MeSH-major] Antiviral Agents / therapeutic use. HIV Infections / drug therapy. Hepatitis C, Chronic / drug therapy. Interferon-alpha / therapeutic use. Ribavirin / therapeutic use
  • [MeSH-minor] Adult. Anemia / chemically induced. CD4 Lymphocyte Count. Drug Interactions. Drug Therapy, Combination. Female. Humans. Male. Polymerase Chain Reaction / methods. Recurrence. Retrospective Studies. Treatment Outcome. Viral Load

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Antimicrob Agents Chemother. 1997 Jun;41(6):1231-6 [9174176.001]
  • [Cites] Science. 1987 Mar 13;235(4794):1376-9 [2435003.001]
  • [Cites] Antimicrob Agents Chemother. 1987 Oct;31(10):1613-7 [3435108.001]
  • [Cites] AIDS. 1990 Jan;4(1):67-72 [1690551.001]
  • [Cites] Clin Infect Dis. 1996 Nov;23(5):1117-25 [8922812.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1493-9 [9819447.001]
  • [Cites] Lancet. 1997 Nov 15;350(9089):1425-31 [9371165.001]
  • [Cites] Lancet. 1998 Jan 10;351(9096):83-7 [9439491.001]
  • [Cites] J Hepatol. 1998 Jun;28(6):945-50 [9672168.001]
  • [Cites] Lancet. 1998 Oct 31;352(9138):1426-32 [9807989.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1485-92 [9819446.001]
  • [CommentIn] Gut. 2000 Nov;47(5):608-9 [11034571.001]
  • (PMID = 11034587.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 49717AWG6K / Ribavirin
  • [Other-IDs] NLM/ PMC1728127
  •  go-up   go-down


37. Tran A, Longo F, Ouzan D, Bianchi D, Pradier C, Saint-Paul MC, Sattonnet C, Laffont C, Dantin S, Piche T, Benzaken S, Rampal P: Effects of 1-year interferon-alpha 2a treatment in patients with chronic hepatitis C and persistently normal transaminase activity. Scand J Gastroenterol; 2000 Apr;35(4):433-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of 1-year interferon-alpha 2a treatment in patients with chronic hepatitis C and persistently normal transaminase activity.
  • The aims of this study were to determine the virologic and histologic effects of 1 year of interferon-alpha treatment in such patients.
  • Eleven accepted interferon-alpha therapy; the 20 others were not treated and served as controls.
  • Interferon-alpha, 3 MU, was given thrice weekly for 1 year.
  • Serum was examined for hepatitis C virus (HCV)-RNA before, at the end of, and 6 months after treatment.
  • Liver biopsy was performed 6 months after the cessation of treatment in 10 of 11 treated patients (one refused biopsy) and after a mean of 30.6+/-22.7 months in the 20 untreated patients.
  • No significant histologic improvement was observed in the treated patients evaluated by means of post-treatment liver biopsy.
  • CONCLUSIONS: One year of interferon-alpha treatment can suppress HCV-RNA in patients with chronic hepatitis C and persistently normal ALAT values followed up over long periods.
  • The rate of fibrosis progression in such patients is very slow, and therapeutic strategies should take this fact into account.
  • Antiviral treatment is debated for patients without fibrosis in initial biopsy specimens.
  • [MeSH-major] Alanine Transaminase / blood. Antiviral Agents / therapeutic use. Hepatitis C, Chronic / drug therapy. Hepatitis C, Chronic / enzymology. Interferon-alpha / therapeutic use
  • [MeSH-minor] Adult. Aged. Biopsy. Chi-Square Distribution. Disease Progression. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. RNA, Viral / blood. Recombinant Proteins. Reverse Transcriptase Polymerase Chain Reaction. Statistics, Nonparametric

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10831269.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] NORWAY
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / RNA, Viral; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down






Advertisement